CombiGene AB (OSTO:COMBI) Debt-to-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is CombiGene AB Debt-to-Asset?

CombiGene AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr0.00 Mil. CombiGene AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr0.00 Mil. CombiGene AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was kr91.18 Mil. CombiGene AB's debt to asset for the quarter that ended in Sep. 2024 was 0.00.

CombiGene AB Debt-to-Asset Historical Data

The historical data trend for CombiGene AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CombiGene AB Debt-to-Asset Chart

CombiGene AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.16

CombiGene AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CombiGene AB's Debt-to-Asset

For the Biotechnology subindustry, CombiGene AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CombiGene AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CombiGene AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where CombiGene AB's Debt-to-Asset falls into.

CombiGene AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

CombiGene AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	120.612
	=	0.00

CombiGene AB's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	91.184
	=	0.00

CombiGene AB (OSTO:COMBI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

CombiGene AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of CombiGene AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CombiGene AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CombiGene AB (OSTO:COMBI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Agavagen 52A, Lidingo, SWE, SE-181 55

Website

https://www.combigene.com

CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. It develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.

CombiGene AB Headlines

No Headlines